Compare Clorox Co (CLX) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Crispr Therapeutics AG — how do they compare? Clorox Co trades at $106.55 (market cap $13.09B), while Crispr Therapeutics AG trades at $54.31 (market cap $5.23B). The key difference: Clorox Co is far larger — about 2.5× Crispr Therapeutics AG's market cap, and Clorox Co pays a 4.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CLX | CRSP | |
|---|---|---|
Market Cap | $13.09B | $5.23B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $76.78 |
52-Week Low | $86.12 | $44.34 |
Enterprise Value | $18.47B | $3.65B |
Dividend Yield | 4.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
